

March 28, 2020

The National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

BSE Limited  
Phiroze Jeejeeboy Towers  
Dalal Street,  
Mumbai- 400 001

Dear Sir/Madam,

Sub: Disclosure under Regulation 29 (1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.


--0--

This is to inform you that pursuant to the Regulation 29 (1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we have received communication from Nalanda India Equity Fund Limited, intimating acquisition of 33,66,371 Nos. of equity shares from the open market, representing 6.37% of paid up capital of the Company.

A copy of their letter along with detailed information as specified in the Format of Regulation 29 (1) of the SEBI (SAST) Regulations, 2011, is enclosed herewith.

Please take the same on record and oblige.

Yours Faithfully,  
For **Thyrocare Technologies Limited**,

  
**Ramjee Dorai**  
Company Secretary and Compliance Officer



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)

# NALANDA INDIA EQUITY FUND LIMITED

---

27 March, 2020

Thyrocare Technologies Limited  
D-37/1, TTC MIDC  
Turbhe,  
Navi Mumbai -400 703

Tel: 022- 3090 0000 / 4125 2525

Kind Attn: Mr. Ramjee Dorai  
Company Secretary and Compliance Officer

Email: investor\_relations@thyrocare.com

Dear Sirs,

**Re: Reporting of acquisition of shares of THYROCARE TECHNOLOGIES LIMITED**

Please find attached the relevant Forms as per the relevant regulations in respect of the above mentioned.

Due to the lockdown we cannot courier the originals today, but the same will follow as soon as possible.

**Please also note that Mauritius has officially gone under confinement due to COVID-19 and the Mauritian authorities have announced a lock down of the island to minimise the impact of the coronavirus for a period of two weeks and as a result our office is also closed.**

**The original document will be couriered to your attention by DHL at the earliest possible.**

Thank you for your attention.

Yours faithfully



---

**Husayn Sassa**  
Director



Annexure-1

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

1.	Name of the Target Company (TC)	THYROCARE TECHNOLOGIES LIMITED		
2.	Name (s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	NALANDA INDIA EQUITY FUND LIMITED		
3.	Whether the acquirer belongs to Promoter/Promoter group	No		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	NSE & BSE		
5.	Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
<u>Before the acquisition under consideration, holding of acquirer along with PACs:</u>				
	a) Shares carrying voting rights	500,000	0.94%	0.94%
	b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
	c) Voting rights (VR) otherwise than by equity shares			
	d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
	e) Total (a+b+c+d)	500,000	0.94%	0.94%

Details of acquisition

a)	Shares carrying voting rights acquired	2,866,371	5.43%	5.43%
b)	VRs acquired otherwise than by equity shares			
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
d)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e)	Total (a+b+c+d)	2,866,371	5.43%	5.43%

After the acquisition, holding of acquirer along with PACs of:

a)	Shares carrying voting rights	3,366,371	6.37%	6.37%
----	-------------------------------	-----------	-------	-------



# भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

b)	VRs otherwise than by equity shares			
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
e)	Total (a+b+c+d)	3,366,371	6.37%	6.37%

6.	Mode of acquisition (eg. Open market / off market / public issues / rights issues / preferential allotment / inter-se transfer etc).	Open Market
7.	Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Securities acquired are ordinary equity shares
8.	Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	25 March 2020
9.	Equity share capital / total voting capital of the TC before the said acquisition	INR 528363650
10.	Equity share capital/ total voting capital of the TC after the said acquisition	INR 528363650
11.	Total diluted share / voting capital of the TC after the said acquisition	INR 528363650

Part-B\*\*\*

Name of the Target Company:

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/ or PACs
NALANDA INDIA EQUITY FUND LIMITED	No	AADCN6131F

Signature of the acquirer / Authorised Signatory

Place:

Mauritius

Date:

27-Mar-20

Note:

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Cl:

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(\*\*\*) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.